Recently, the 2026 Xiding Conference was grandly held. As one of China's most influential annual events in the health industry, this edition gathered thousands of national chain terminals, industry elites, and industry partners to discuss industry trends. JumpCan Pharmaceutical showcased two flagship innovative drugs: dermatology innovative drug Zelimei (Benvitimod Cream) completed its blockbuster specialty debut, while anti-influenza innovative drug Jikeshu (Sebaloxavir Marboxil Tablets) won an industry award with its solid strength. Wang Xiaobing, Deputy General Manager of JumpCan Pharmaceutical Group, was invited to attend the award ceremony. JumpCan Pharmaceutical demonstrated its innovation, R&D and commercialization capabilities with the combined brilliance of both drugs, reflecting the responsibility and commitment of a national pharmaceutical enterprise.

 

 

Blockbuster Debut at Xiding! Zelimei Opens a New Era of Non-Hormonal AD Treatment

 

The Xiding Conference is an important platform connecting the industry, chains, terminals, and consumers, and a core stage for companies to showcase innovative achievements and convey brand value. At this year's Xiding Conference, JumpCan Pharmaceutical held a specialty debut ceremony for Zelimei (Benvitimod Cream), releasing this milestone dermatological new drug to the entire industry — reflecting the company's strategic deployment in the out-of-hospital market and commitment to serving patients, as well as a confident display of innovative achievements.

 

Zelimei (Benvitimod Cream) is an innovative drug independently developed by Shanghai Thederma Medical Technology Co., Ltd. with an entirely new mechanism of action and target. It is also the world's first aryl hydrocarbon receptor (AhR) modulator approved for the treatment of mild to moderate atopic dermatitis in children aged 2 years and older and adults. JumpCan Pharmaceutical holds exclusive commercialization rights for Zelimei (Benvitimod Cream) in the People's Republic of China (excluding the Hong Kong and Macao Special Administrative Regions and Taiwan, China).

 

 

At the event, Dr. Yi Qianhui, Medical Director of thederma, elaborated in detail on Zelimei's four core advantages: non-hormonal, effective, low recurrence, and suitable for children. The presentation attracted many chain partners and industry experts to stop and engage in deep exchanges, making Zelimei one of the most-watched innovative products at this year's Xiding Conference — fully reflecting the industry's and market's high recognition of JumpCan Pharmaceutical's innovation and transformation. Zelimei (Benvitimod Cream), addressing clinical pain points, fills the need for safe, long-acting, child-friendly non-hormonal therapeutic drugs, and has received recommendations from multiple authoritative domestic and international guidelines, bringing better treatment options for countless atopic dermatitis patients.

 

 

Jikeshu Wins the "Most Promising Innovative Drug" Title

 

In the key award selection at this year's Xiding Conference, anti-influenza innovative drug Jikeshu (Sebaloxavir Marboxil Tablets) — by virtue of its outstanding clinical value, broad market potential, and high industry recognition — successfully won the "Future King" "2025–2026 China Pharmaceutical Retail Market Most Promising Innovative Drug" award. This honor is not only an authoritative industry endorsement of Jikeshu's anti-influenza drug capabilities, but also marks its core value in China's pharmaceutical retail market being highly recognized, establishing it as a benchmark product in the anti-influenza race.

 

As influenza prevention and control enters normalized management, the demand for innovative anti-influenza drugs at retail terminals continues to grow. With its core values of high efficiency and convenience demonstrated by "one dose for the full treatment course," Jikeshu has become a core single product for pharmacies to enrich anti-influenza product categories and enhance professional service capabilities — providing national chain pharmacies with a more market-potential innovative choice, helping retail terminals improve respiratory drug coverage and better serve public health.

 

 

Innovation and Transformation: Protecting Public Health with Quality Pharmaceutical

 

From the blockbuster debut of a dermatology innovative drug to an anti-influenza innovative drug returning with honors, the corporate innovation capabilities behind these products are JumpCan Pharmaceutical's core competitive strength in responding to market changes. JumpCan Pharmaceutical anchors its advantages in respiratory, pediatrics, gastroenterology areas to solidify its foundation, deploys in dermatology and cardiovascular areas, and expands its boundaries through dual-wheel drive of "innovative drugs + new pipeline." In the innovative drug arena, the commercial launches of Jikeshu, Zelimei , and Yixining mark the company's deep transformation toward "innovation-driven" development; on the new pipeline side, long-acting growth hormones, pediatric chronic constipation, postoperative intestinal function recovery, and moderate-to-severe psoriasis are continuously advancing, forming a product matrix of "steady development of mature products, expansion of incremental products with innovative ones."This enables JumpCan Pharmaceutical to maintain dual agility in technology iteration and market response against the backdrop of pharmaceutical policy adjustments and evolving market demands.

 

Standing at the temporal coordinates of the deepening implementation of the Healthy China strategy, JumpCan Pharmaceutical upholds the corporate vision of "build a joyful and vibrant life together" and continues to move toward the practical direction of "bringing patients multidimensional health upgrade experiences." In the future, the company will continue to use innovation-driven development as its core engine, deeply excavate clinical needs in its advantage areas, respond to market expectations with richer innovative achievements, and inject JumpCan's momentum into the development of the broader health industry.